Literature DB >> 8840962

Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.

K Scotlandi1, S Benini, M Sarti, M Serra, P L Lollini, D Maurici, P Picci, M C Manara, N Baldini.   

Abstract

The disappointingly low survival rate observed in Ewing's sarcoma (ES)/peripheral neuroectodermal tumor (PNET) despite the adoption of aggressive multimodal treatments prompted us to study the existence of autocrine circuits to be used as innovative therapeutic targets. Of the several circuits analyzed, only the insulin-like growth factor receptor (IGF-IR)-mediated loop was found to be constantly present both in cell lines and clinical samples, suggesting a role for this autocrine circuit in the pathogenesis of ES/PNET. The in vitro inhibition of the IGF-IR-mediated circuit by the specific IGF-IR binding antibody alphaIR3 suppressed the growth of ES/PNET cells by decreasing the proliferative rate and increasing apoptosis. alphaIR3 also significantly inhibited the ability of ES/PNET cells to grow in soft agar and to migrate following a chemotactic stimulus. Inactivation of the IGF-IR signaling pathway may therefore be considered as an effective therapeutic modality for patients with ES/PNET.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  86 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.

Authors:  Lillian M Guenther; Neekesh V Dharia; Linda Ross; Amy Conway; Amanda L Robichaud; Jerrel L Catlett; Caroline S Wechsler; Elizabeth S Frank; Amy Goodale; Alanna J Church; Yuen-Yi Tseng; Rajarshi Guha; Crystal G McKnight; Katherine A Janeway; Jesse S Boehm; Jaume Mora; Mindy I Davis; Gabriela Alexe; Federica Piccioni; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2018-11-05       Impact factor: 12.531

3.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

5.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

Review 6.  Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.

Authors:  Sandra J Strauss; Tony Ng; Ariadna Mendoza-Naranjo; Jeremy Whelan; Poul H B Sorensen
Journal:  Oncologist       Date:  2010-05-17

7.  IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Brian A Menegaz; Vandhana Ramamoorthy; Deeksha Vishwamitra; Ying Wang; Rebecca L Maywald; Adriana S Buford; Izabela Fokt; Stanislaw Skora; Jing Wang; Aung Naing; Alexander J Lazar; Eric M Rohren; Najat C Daw; Vivek Subbiah; Robert S Benjamin; Ravin Ratan; Waldemar Priebe; Antonios G Mikos; Hesham M Amin; Joseph A Ludwig
Journal:  J Natl Cancer Inst       Date:  2016-08-30       Impact factor: 13.506

8.  Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.

Authors:  Allison F O'Neill; Jason L J Dearling; Yuchuan Wang; Tanya Tupper; Yanping Sun; Jon C Aster; Monica L Calicchio; Antonio R Perez-Atayde; Alan B Packard; Andrew L Kung
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

Review 9.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 10.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.